AroCell announces that quantitative point-of-care (POC) oncology product UBC Rapid has been verified for results interpretation on a new instrument, the Cube Reader. By differentiating UBC® Rapid and addressing the different needs of end-users, the possibility of a more widespread use increases. The Cube Reader is manufactured by the same company (Chembio Diagnostics Inc.) as the concile 100, which is currently exclusively used for interpretation of UBC® Rapid.

The Cube Reader is a user-friendly, portable, palm-sized device that complements the concile 100 by better suiting simpler POC settings. Bladder Cancer has the higher lifetime treatment cost per patient due to a high likelihood of recurrence and long-term invasive follow-up. Unfortunately, the need for cost-effective, non-invasive, and simple POC tools to minimize the healthcare burden will increase due to a worldwide aging population.

The use of UBC® Rapid would reduce this burden due to the versatility of its applications, both as an aid in diagnosis and during the long follow-up period.